Liminatus Pharma (LIMN) Fundamental Analysis: Revenue, Earnings & Valuation

9.00 / 10

Outperform

Fundamental analysis rates LIMN Outperform with a 9.0/10 score. Strengths include high interest coverage and favorable Revenue‑MV, while long‑term debt to working capital and current liabilities ratios are weak. Overall, the balance sheet and earnings quality are robust.

Analysis Checks(8/10)

Revenue-MV

Value-0.28

Score3/3

Weight39.82%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value78.03

Score2/3

Weight0.55%

1M Return0.13%

Inventory turnover ratio

Value47.95

Score2/3

Weight-4.54%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value95.86

Score0/3

Weight-16.82%

1M Return-4.96%

PB-ROE

Value31.30

Score2/3

Weight37.14%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value26.96

Score0/3

Weight-17.30%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-4.62%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value92.19

Score2/3

Weight0.22%

1M Return0.05%

Cost of sales ratio (%)

Value70.31

Score2/3

Weight-4.36%

1M Return-1.13%

Asset-MV

Value-0.49

Score3/3

Weight69.91%

1M Return11.61%

Is LIMN undervalued or overvalued?

LIMN scores 9.00/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -0.78 P/E ratio, -0.81 P/B ratio, and -115.00% earnings growth, these metrics solidify its Outperform investment rating.